Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

Neurology

Volumn 69, Issue 8, 2007, Pages 785-789

  Rose, J W ^a,b,c,d   Burns, J B ^a,b   Bjorklund, J ^a   Klein, J ^a,b   Watt, H E ^a   Carlson, N G ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d VA SLC HCS (151B)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA1A INTERFERON; COTRIMOXAZOLE; DACLIZUMAB; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LUNG INFILTRATE; LYMPHADENOPATHY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RATING SCALE; RELAPSE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; INTERFERON-BETA; INTERFERONS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHATIC DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 34548142973     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000267662.41734.1f     Document Type: Article

References (18)

1. Noseworthy J. Multiple sclerosis, N Engl J Med 2000;343:938-952.
2. Brashir and Whitacker J. Current immunotherapy for demyelinating diseases. Arch Neurol 2002;59:726-731.
3. Waldmann T, Levy R, Coller B. Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2000;394-406.
4. Morris JC, Waldmann T. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000;59(suppl 1):i109-i114.
5. Rose J, Lorberboum-Galski H, Fitzgerald D, Hill K, Townsend J, Pastan I. Chimeric cytotoxin IL2-PE40 inhibits EAE in the adoptive transfer model. J Neuroimmunol 1991;32:209-217.
6. Hayosh N, Swanborg R. Autoimmune effector cells: IX. Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors. J Immunol 1987;138:3771-3775.
7. Engelhardt B, Diamanstein T, Wekerle H. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J Autoimmun 1989;2:61-73.
8. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-165.
9. Nussenblatt R, Fortin E, Schiffman, Rizzo L, et al. Treatment of noninfectious intermediate and posterior uveitis with humanized anti-TAC mAb: a phase I/II clinical trial. Proc Natl Acad Sci 1999;96:7462-7466.
10. Beilekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci 2004;101:8705-8708.
11. Rose J, Watt H, White A, Carlson N. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-867.
12. Keisu M, Wilhom B, Palmblad J. Trimethoprim-sulphamethoxazole associated blood dyscrasias. Ten year's experience of the Swedish spontaneous reporting system. J Intern Med 1990;228:353-360.
13. Pedersen-Bjergaard U, Adersen M, Hansen P. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-1991. J Intern Med 1996;239:509-515.
14. Herringtion A, Mahmood A, Berger R. Treatment options in sulfamethoxazole-trimethoprim induced thrombocytopenia. South Med J 1994;87:948-950.
15. Prisms Study Group. Randomized double-blind placebo-controlled study of interferon b1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
16. Fogarty P, Seggweiss R, McCloskey D, Boss C, Dunbar C, Rick M. Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenia. Hematologica 2006;91:277-278.
17. Beilekova B, Catakfamo M, Reichert-Scrivner S, et al. Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2α-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 2006;103:5941-5946.
18. Snyder J, Shen J, Azmi H, Hou J, Fowler D, Ragheb J. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007;109:5399-5406.